;PMID: 9839089
;source_file_1871.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..122] = [t:48..122]
;2)section:[e:126..140] = [t:126..140]
;3)section:[e:144..223] = [t:144..223]
;4)sentence:[e:227..358] = [t:227..358]
;5)sentence:[e:359..457] = [t:359..457]
;6)sentence:[e:458..560] = [t:458..560]
;7)sentence:[e:561..722] = [t:561..722]
;8)sentence:[e:723..857] = [t:723..857]
;9)sentence:[e:858..1021] = [t:858..1021]
;10)sentence:[e:1022..1194] = [t:1022..1194]
;11)sentence:[e:1195..1341] = [t:1195..1341]
;12)sentence:[e:1342..1446] = [t:1342..1446]
;13)sentence:[e:1447..1637] = [t:1447..1637]
;14)sentence:[e:1638..1866] = [t:1638..1866]
;15)sentence:[e:1867..2111] = [t:1867..2111]
;16)sentence:[e:2112..2330] = [t:2112..2330]
;17)sentence:[e:2331..2586] = [t:2331..2586]
;18)sentence:[e:2587..2750] = [t:2587..2750]
;19)sentence:[e:2751..2889] = [t:2751..2889]
;20)section:[e:2893..2911] = [t:2893..2911]
;21)section:[e:2917..2923] = [t:2917..2923]
;22)section:[e:2929..2945] = [t:2929..2945]
;23)section:[e:2949..2993] = [t:2949..2993]

;section 0 Span:0..42
;Clin Pharmacokinet. 1998 Nov;35(5):361-90.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..18] Pharmacokinet) (.:[18..19] .)
        (CD:[20..24] 1998) (NNP:[25..28] Nov) (::[28..29] ;) (CD:[29..31] 35)
        (-LRB-:[31..32] -LRB-) (CD:[32..33] 5) (-RRB-:[33..34] -RRB-)
        (::[34..35] :) (CD:[35..38] 361) (HYPH:[38..39] -) (CD:[39..41] 90)
        (.:[41..42] .)))

;sentence 1 Span:48..122
;Inhibition and induction of cytochrome P450 and the clinical implications.
;[76..91]:cyp450:"cytochrome P450"
(SENT
  (NP-HLN
    (NP (NN:[48..58] Inhibition)
      (NP (CC:[59..62] and) (NN:[63..72] induction))
      (PP (IN:[73..75] of)
        (NP (NN:[76..86] cytochrome) (NN:[87..91] P450))))
    (CC:[92..95] and)
    (NP (DT:[96..99] the) (JJ:[100..108] clinical) (NNS:[109..121] implications))
    (.:[121..122] .)))

;section 2 Span:126..140
;Lin JH, Lu AY.
(SEC
  (FRAG (NNP:[126..129] Lin) (NNP:[130..132] JH) (,:[132..133] ,)
        (NNP:[134..136] Lu) (NNP:[137..139] AY) (.:[139..140] .)))

;section 3 Span:144..223
;Merck Research Laboratories, West Point, Pennsylvania, USA.
;jiunn_lin@merck.com
(SEC
  (FRAG (NNP:[144..149] Merck) (NNP:[150..158] Research)
        (NNP:[159..171] Laboratories) (,:[171..172] ,) (NNP:[173..177] West)
        (NNP:[178..183] Point) (,:[183..184] ,) (NNP:[185..197] Pennsylvania)
        (,:[197..198] ,) (NNP:[199..202] USA) (.:[202..203] .)
        ('':[204..223] jiunn_lin@merck.com)))

;sentence 4 Span:227..358
;The cytochrome P450s (CYPs) constitute a superfamily of isoforms that play an
; important role in the oxidative metabolism of drugs.
;[231..247]:cyp450:"cytochrome P450s"
;[249..253]:cyp450:"CYPs"
;[283..291]:cyp450:"isoforms"
;[352..357]:substance:"drugs"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[227..230] The)
         (NN:[231..241] cytochrome) (NNS:[242..247] P450s))
      (NP (-LRB-:[248..249] -LRB-) (NNS:[249..253] CYPs)
          (-RRB-:[253..254] -RRB-)))
    (VP (VBP:[255..265] constitute)
      (NP
        (NP (DT:[266..267] a) (NN:[268..279] superfamily))
        (PP (IN:[280..282] of)
          (NP
            (NP (NNS:[283..291] isoforms))
            (SBAR
              (WHNP-1 (WDT:[292..296] that))
              (S
                (NP-SBJ-1 (-NONE-:[296..296] *T*))
                (VP (VBP:[297..301] play)
                  (NP (DT:[302..304] an) (JJ:[306..315] important)
                      (NN:[316..320] role))
                  (PP (IN:[321..323] in)
                    (NP
                      (NP (DT:[324..327] the) (JJ:[328..337] oxidative)
                          (NN:[338..348] metabolism))
                      (PP (IN:[349..351] of)
                        (NP (NNS:[352..357] drugs))))))))))))
    (.:[357..358] .)))

;sentence 5 Span:359..457
;Each CYP isoform possesses  a characteristic broad spectrum of catalytic
;activities of substrates.
;[364..375]:cyp450:"CYP isoform"
;[446..456]:substance:"substrates"
(SENT
  (S
    (NP-SBJ (DT:[359..363] Each)
       (NN:[364..367] CYP) (NN:[368..375] isoform))
    (VP (VBZ:[376..385] possesses)
      (NP
        (NP (DT:[387..388] a) (JJ:[389..403] characteristic)
            (JJ:[404..409] broad) (NN:[410..418] spectrum))
        (PP (IN:[419..421] of)
          (NP
            (NP (JJ:[422..431] catalytic) (NNS:[432..442] activities))
            (PP (IN:[443..445] of)
              (NP (NNS:[446..456] substrates)))))))
    (.:[456..457] .)))

;sentence 6 Span:458..560
;Whenever  2 or more drugs are administered concurrently, the possibility of
;drug  interactions exists.
;[478..483]:substance:"drugs"
;[534..538]:substance:"drug"
(SENT
  (S
    (SBAR-ADV (IN:[458..466] Whenever)
      (S
        (NP-SBJ-1
          (QP (CD:[468..469] 2) (CC:[470..472] or) (JJR:[473..477] more))
          (NNS:[478..483] drugs))
        (VP (VBP:[484..487] are)
          (VP (VBN:[488..500] administered)
            (NP-1 (-NONE-:[500..500] *))
            (ADVP-MNR (RB:[501..513] concurrently))))))
    (,:[513..514] ,)
    (NP-SBJ
      (NP (DT:[515..518] the) (NN:[519..530] possibility))
      (PP (IN:[531..533] of)
        (NP (NN:[534..538] drug) (NNS:[540..552] interactions))))
    (VP (VBZ:[553..559] exists))
    (.:[559..560] .)))

;sentence 7 Span:561..722
;The ability of a single CYP to metabolise multiple  substrates is responsible
;for a large number of documented drug interactions  associated with CYP
;inhibition.
;[585..588]:cyp450:"CYP"
;[613..623]:substance:"substrates"
;[672..676]:substance:"drug"
;[707..710]:cyp450:"CYP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[561..564] The) (NN:[565..572] ability)
        (S-1 (-NONE-:[572..572] *ICH*)))
      (PP (IN:[573..575] of)
        (NP (DT:[576..577] a) (JJ:[578..584] single) (NN:[585..588] CYP)))
      (S-1
        (NP-SBJ (-NONE-:[588..588] *))
        (VP (TO:[589..591] to)
          (VP (VB:[592..602] metabolise)
            (NP (JJ:[603..611] multiple) (NNS:[613..623] substrates))))))
    (VP (VBZ:[624..626] is)
      (ADJP-PRD (JJ:[627..638] responsible)
        (PP (IN:[639..642] for)
          (NP
            (NP (DT:[643..644] a) (JJ:[645..650] large) (NN:[651..657] number))
            (PP (IN:[658..660] of)
              (NP
                (NP (VBN:[661..671] documented) (NN:[672..676] drug)
                    (NNS:[677..689] interactions))
                (VP (VBN:[691..701] associated)
                  (NP (-NONE-:[701..701] *))
                  (PP-CLR (IN:[702..706] with)
                    (NP (NN:[707..710] CYP) (NN:[711..721] inhibition))))))))))
    (.:[721..722] .)))

;sentence 8 Span:723..857
;In addition, drug interactions can also occur as  a result of the induction
;of several human CYPs following long term drug  treatment.
;[736..740]:substance:"drug"
;[816..820]:cyp450:"CYPs"
;[841..845]:substance:"drug"
(SENT
  (S
    (PP (IN:[723..725] In)
      (NP (NN:[726..734] addition)))
    (,:[734..735] ,)
    (NP-SBJ (NN:[736..740] drug) (NNS:[741..753] interactions))
    (VP (MD:[754..757] can)
      (ADVP (RB:[758..762] also))
      (VP (VB:[763..768] occur)
        (PP (IN:[769..771] as)
          (NP
            (NP (DT:[773..774] a) (NN:[775..781] result))
            (PP (IN:[782..784] of)
              (NP
                (NP (DT:[785..788] the) (NN:[789..798] induction))
                (PP (IN:[799..801] of)
                  (NP (JJ:[802..809] several) (JJ:[810..815] human)
                      (NNS:[816..820] CYPs)))))))
        (S
          (NP-SBJ (-NONE-:[820..820] *))
          (VP (VBG:[821..830] following)
            (NP
              (NML (JJ:[831..835] long) (NN:[836..840] term))
              (NN:[841..845] drug) (NN:[847..856] treatment))))))
    (.:[856..857] .)))

;sentence 9 Span:858..1021
;The mechanisms of CYP inhibition can be divided into 3 categories:  (a)
;reversible inhibition; (b) quasi-irreversible inhibition; and (c) 
;irreversible inhibition.
;[876..879]:cyp450:"CYP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[858..861] The) (NNS:[862..872] mechanisms))
      (PP (IN:[873..875] of)
        (NP (NN:[876..879] CYP) (NN:[880..890] inhibition))))
    (VP (MD:[891..894] can)
      (VP (VB:[895..897] be)
        (VP (VBN:[898..905] divided)
          (NP-1 (-NONE-:[905..905] *))
          (PP-CLR (IN:[906..910] into)
            (NP
              (NP (CD:[911..912] 3) (NNS:[913..923] categories))
              (::[923..924] :)
              (NP
                (NP
                  (LST (LS:[926..929] -LRB-a-RRB-))
                  (JJ:[930..940] reversible) (NN:[941..951] inhibition))
                (::[951..952] ;)
                (NP
                  (LST (LS:[953..956] -LRB-b-RRB-))
                  (ADJP (AFX:[957..962] quasi) (HYPH:[962..963] -)
                        (JJ:[963..975] irreversible))
                  (NN:[976..986] inhibition))
                (::[986..987] ;) (CC:[988..991] and)
                (NP
                  (LST (LS:[992..995] -LRB-c-RRB-))
                  (JJ:[997..1009] irreversible) (NN:[1010..1020] inhibition))))))))
    (.:[1020..1021] .)))

;sentence 10 Span:1022..1194
;In mechanistic terms, reversible interactions arise as  a result of
;competition at the CYP active site and probably involve only the  first step
;of the CYP catalytic cycle.
;[1109..1112]:cyp450:"CYP"
;[1174..1177]:cyp450:"CYP"
(SENT
  (S
    (PP (IN:[1022..1024] In)
      (NP (JJ:[1025..1036] mechanistic) (NNS:[1037..1042] terms)))
    (,:[1042..1043] ,)
    (NP-SBJ (JJ:[1044..1054] reversible) (NNS:[1055..1067] interactions))
    (VP
      (VP (VBP:[1068..1073] arise)
        (PP (IN:[1074..1076] as)
          (NP
            (NP (DT:[1078..1079] a) (NN:[1080..1086] result))
            (PP (IN:[1087..1089] of)
              (NP
                (NP (NN:[1090..1101] competition))
                (PP-LOC (IN:[1102..1104] at)
                  (NP (DT:[1105..1108] the) (NN:[1109..1112] CYP)
                      (JJ:[1113..1119] active) (NN:[1120..1124] site))))))))
      (CC:[1125..1128] and)
      (VP
        (ADVP (RB:[1129..1137] probably))
        (VBP:[1138..1145] involve)
        (NP
          (NP (RB:[1146..1150] only) (DT:[1151..1154] the)
              (JJ:[1156..1161] first) (NN:[1162..1166] step))
          (PP (IN:[1167..1169] of)
            (NP (DT:[1170..1173] the) (NN:[1174..1177] CYP)
                (JJ:[1178..1187] catalytic) (NN:[1188..1193] cycle))))))
    (.:[1193..1194] .)))

;sentence 11 Span:1195..1341
;On the other hand, drugs that act during  and subsequent to the oxygen
;transfer step are generally irreversible or  quasi-irreversible inhibitors.
;[1214..1219]:substance:"drugs"
;[1259..1265]:substance:"oxygen"
;[1330..1340]:substance:"inhibitors"
(SENT
  (S
    (PP (IN:[1195..1197] On)
      (NP (DT:[1198..1201] the) (JJ:[1202..1207] other) (NN:[1208..1212] hand)))
    (,:[1212..1213] ,)
    (NP-SBJ
      (NP (NNS:[1214..1219] drugs))
      (SBAR
        (WHNP-3 (WDT:[1220..1224] that))
        (S
          (NP-SBJ-3 (-NONE-:[1224..1224] *T*))
          (VP (VBP:[1225..1228] act)
            (UCP-TMP
              (PP (IN:[1229..1235] during)
                (NP-2 (-NONE-:[1235..1235] *RNR*)))
              (CC:[1237..1240] and)
              (ADJP (JJ:[1241..1251] subsequent)
                (PP (TO:[1252..1254] to)
                  (NP-2 (-NONE-:[1254..1254] *RNR*))))
              (NP-2 (DT:[1255..1258] the)
                (NML (NN:[1259..1265] oxygen) (NN:[1266..1274] transfer))
                (NN:[1275..1279] step)))))))
    (VP (VBP:[1280..1283] are)
      (ADVP (RB:[1284..1293] generally))
      (NP-PRD
        (NP (JJ:[1294..1306] irreversible)
          (NML-1 (-NONE-:[1306..1306] *P*)))
        (CC:[1307..1309] or)
        (NP
          (ADJP (AFX:[1311..1316] quasi) (HYPH:[1316..1317] -)
                (JJ:[1317..1329] irreversible))
          (NML-1 (NNS:[1330..1340] inhibitors)))))
    (.:[1340..1341] .)))

;sentence 12 Span:1342..1446
;Irreversible and quasi-irreversible inhibition  require at least one cycle of
;the CYP catalytic process.
;[1424..1427]:cyp450:"CYP"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1342..1354] Irreversible)
        (NML-1 (-NONE-:[1354..1354] *P*)))
      (CC:[1355..1358] and)
      (NP
        (ADJP (AFX:[1359..1364] quasi) (HYPH:[1364..1365] -)
              (JJ:[1365..1377] irreversible))
        (NML-1 (NN:[1378..1388] inhibition))))
    (VP (VBP:[1390..1397] require)
      (NP
        (NP
          (QP (IN:[1398..1400] at) (JJS:[1401..1406] least)
              (CD:[1407..1410] one))
          (NN:[1411..1416] cycle))
        (PP (IN:[1417..1419] of)
          (NP (DT:[1420..1423] the) (NN:[1424..1427] CYP)
              (JJ:[1428..1437] catalytic) (NN:[1438..1445] process)))))
    (.:[1445..1446] .)))

;sentence 13 Span:1447..1637
;Because human liver  samples and recombinant human CYPs are now readily
;available, in vitro systems  have been used as screening tools to predict the
;potential for in vivo drug  interaction.
;[1498..1502]:cyp450:"CYPs"
;[1619..1623]:substance:"drug"
(SENT
  (S
    (SBAR-ADV (IN:[1447..1454] Because)
      (S
        (NP-SBJ
          (NP (JJ:[1455..1460] human) (NN:[1461..1466] liver)
              (NNS:[1468..1475] samples))
          (CC:[1476..1479] and)
          (NP (JJ:[1480..1491] recombinant) (JJ:[1492..1497] human)
              (NNS:[1498..1502] CYPs)))
        (VP (VBP:[1503..1506] are)
          (ADVP-TMP (RB:[1507..1510] now))
          (ADJP-PRD (RB:[1511..1518] readily) (JJ:[1519..1528] available)))))
    (,:[1528..1529] ,)
    (NP-SBJ-1
      (ADJP (FW:[1530..1532] in) (FW:[1533..1538] vitro))
      (NNS:[1539..1546] systems))
    (VP (VBP:[1548..1552] have)
      (VP (VBN:[1553..1557] been)
        (VP (VBN:[1558..1562] used)
          (NP-1 (-NONE-:[1562..1562] *))
          (PP (IN:[1563..1565] as)
            (NP (VBG:[1566..1575] screening) (NNS:[1576..1581] tools)))
          (S-PRP
            (NP-SBJ (-NONE-:[1581..1581] *))
            (VP (TO:[1582..1584] to)
              (VP (VB:[1585..1592] predict)
                (NP
                  (NP (DT:[1593..1596] the) (NN:[1597..1606] potential))
                  (PP (IN:[1607..1610] for)
                    (NP
                      (ADJP (FW:[1611..1613] in) (FW:[1614..1618] vivo))
                      (NN:[1619..1623] drug) (NN:[1625..1636] interaction))))))))))
    (.:[1636..1637] .)))

;sentence 14 Span:1638..1866
;Although it is easy to determine in vitro metabolic drug  interactions, the
;proper interpretation and extrapolation of in vitro  interaction data to in
;vivo situations require a good understanding of  pharmacokinetic principles.
;[1690..1694]:substance:"drug"
(SENT
  (S
    (SBAR-ADV (IN:[1638..1646] Although)
      (S
        (NP-SBJ (PRP:[1647..1649] it))
        (VP (VBZ:[1650..1652] is)
          (ADJP-PRD (JJ:[1653..1657] easy)
            (S
              (NP-SBJ (-NONE-:[1657..1657] *))
              (VP (TO:[1658..1660] to)
                (VP (VB:[1661..1670] determine)
                  (NP
                    (ADJP (FW:[1671..1673] in) (FW:[1674..1679] vitro))
                    (JJ:[1680..1689] metabolic) (NN:[1690..1694] drug)
                     (NNS:[1696..1708] interactions)))))))))
    (,:[1708..1709] ,)
    (NP-SBJ
      (NP (DT:[1710..1713] the)
        (NML
          (NML
            (ADJP-1 (JJ:[1714..1720] proper))
            (NN:[1721..1735] interpretation))
          (CC:[1736..1739] and)
          (NML
            (ADJP-1 (-NONE-:[1739..1739] *P*))
            (NN:[1740..1753] extrapolation))))
      (PP (IN:[1754..1756] of)
        (NP
          (ADJP (FW:[1757..1759] in) (FW:[1760..1765] vitro))
          (NN:[1767..1778] interaction) (NNS:[1779..1783] data)))
      (PP (TO:[1784..1786] to)
        (NP
          (ADJP (FW:[1787..1789] in) (FW:[1790..1794] vivo))
          (NNS:[1795..1805] situations))))
    (VP (VBP:[1806..1813] require)
      (NP
        (NP (DT:[1814..1815] a) (JJ:[1816..1820] good)
            (NN:[1821..1834] understanding))
        (PP (IN:[1835..1837] of)
          (NP (JJ:[1839..1854] pharmacokinetic) (NNS:[1855..1865] principles)))))
    (.:[1865..1866] .)))

;sentence 15 Span:1867..2111
;From the viewpoint of drug therapy, to avoid  potential drug-drug
;interactions, it is desirable to develop a new drug  candidate that is not a
;potent CYP inhibitor or inducer and the metabolism of  which is not readily
;inhibited by other drugs.
;[1889..1893]:substance:"drug"
;[1923..1927]:substance:"drug"
;[1928..1932]:substance:"drug"
;[1980..1984]:substance:"drug"
;[2017..2020]:cyp450:"CYP"
;[2021..2030]:substance:"inhibitor"
;[2034..2041]:substance:"inducer"
;[2105..2110]:substance:"drugs"
(SENT
  (S
    (PP (IN:[1867..1871] From)
      (NP
        (NP (DT:[1872..1875] the) (NN:[1876..1885] viewpoint))
        (PP (IN:[1886..1888] of)
          (NP (NN:[1889..1893] drug) (NN:[1894..1901] therapy)))))
    (,:[1901..1902] ,)
    (S-PRP
      (NP-SBJ (-NONE-:[1902..1902] *))
      (VP (TO:[1903..1905] to)
        (VP (VB:[1906..1911] avoid)
          (NP (JJ:[1913..1922] potential)
            (NML (NN:[1923..1927] drug) (HYPH:[1927..1928] -)
                 (NN:[1928..1932] drug))
            (NNS:[1933..1945] interactions)))))
    (,:[1945..1946] ,)
    (NP-SBJ (PRP:[1947..1949] it))
    (VP (VBZ:[1950..1952] is)
      (ADJP-PRD (JJ:[1953..1962] desirable))
      (S-ADV
        (NP-SBJ (-NONE-:[1962..1962] *))
        (VP (TO:[1963..1965] to)
          (VP (VB:[1966..1973] develop)
            (NP
              (NP (DT:[1974..1975] a) (JJ:[1976..1979] new)
                  (NN:[1980..1984] drug) (NN:[1986..1995] candidate))
              (SBAR
                (SBAR
                  (WHNP-3 (WDT:[1996..2000] that))
                  (S
                    (NP-SBJ-3 (-NONE-:[2000..2000] *T*))
                    (VP (VBZ:[2001..2003] is) (RB:[2004..2007] not)
                      (NP-PRD (DT:[2008..2009] a)
                        (NML
                          (NML
                            (ADJP-1 (JJ:[2010..2016] potent))
                            (NML-2 (NN:[2017..2020] CYP))
                            (NN:[2021..2030] inhibitor))
                          (CC:[2031..2033] or)
                          (NML
                            (ADJP-1 (-NONE-:[2033..2033] *P*))
                            (NML-2 (-NONE-:[2033..2033] *P*))
                            (NN:[2034..2041] inducer)))))))
                (CC:[2042..2045] and)
                (SBAR
                  (WHNP-4
                    (NP (DT:[2046..2049] the) (NN:[2050..2060] metabolism))
                    (WHPP (IN:[2061..2063] of)
                      (WHNP (WDT:[2065..2070] which))))
                  (S
                    (NP-SBJ-4 (-NONE-:[2070..2070] *T*))
                    (VP (VBZ:[2071..2073] is) (RB:[2074..2077] not)
                      (ADVP (RB:[2078..2085] readily))
                      (VP (VBN:[2086..2095] inhibited)
                        (NP-4 (-NONE-:[2095..2095] *))
                        (PP (IN:[2096..2098] by)
                          (NP-LGS (JJ:[2099..2104] other)
                                  (NNS:[2105..2110] drugs)))))))))))))
    (.:[2110..2111] .)))

;sentence 16 Span:2112..2330
;In reality, drug interaction by  mutual inhibition between drugs is almost
;inevitable, because CYP-mediated  metabolism represents a major route of
;elimination of many drugs, which can  compete for the same CYP enzyme.
;[2124..2128]:substance:"drug"
;[2171..2176]:substance:"drugs"
;[2207..2210]:cyp450:"CYP"
;[2280..2285]:substance:"drugs"
;[2319..2329]:cyp450:"CYP enzyme"
(SENT
  (S
    (PP (IN:[2112..2114] In)
      (NP (NN:[2115..2122] reality)))
    (,:[2122..2123] ,)
    (NP-SBJ
      (NP (NN:[2124..2128] drug) (NN:[2129..2140] interaction))
      (PP (IN:[2141..2143] by)
        (NP
          (NP (JJ:[2145..2151] mutual) (NN:[2152..2162] inhibition))
          (PP (IN:[2163..2170] between)
            (NP (NNS:[2171..2176] drugs))))))
    (VP (VBZ:[2177..2179] is)
      (ADJP-PRD (RB:[2180..2186] almost) (JJ:[2187..2197] inevitable))
      (,:[2197..2198] ,)
      (SBAR-PRP (IN:[2199..2206] because)
        (S
          (NP-SBJ
            (ADJP (NN:[2207..2210] CYP) (HYPH:[2210..2211] -)
                  (VBN:[2211..2219] mediated))
            (NN:[2221..2231] metabolism))
          (VP (VBZ:[2232..2242] represents)
            (NP
              (NP (DT:[2243..2244] a) (JJ:[2245..2250] major)
                  (NN:[2251..2256] route))
              (PP (IN:[2257..2259] of)
                (NP
                  (NP (NN:[2260..2271] elimination))
                  (PP (IN:[2272..2274] of)
                    (NP
                      (NP (JJ:[2275..2279] many) (NNS:[2280..2285] drugs))
                      (,:[2285..2286] ,)
                      (SBAR
                        (WHNP-1 (WDT:[2287..2292] which))
                        (S
                          (NP-SBJ-1 (-NONE-:[2292..2292] *T*))
                          (VP (MD:[2293..2296] can)
                            (VP (VB:[2298..2305] compete)
                              (PP (IN:[2306..2309] for)
                                (NP (DT:[2310..2313] the) (JJ:[2314..2318] same)
                                   (NN:[2319..2322] CYP)
                                   (NN:[2323..2329] enzyme))))))))))))))))
    (.:[2329..2330] .)))

;sentence 17 Span:2331..2586
;The clinical significance of a metabolic drug  interaction depends on the
;magnitude of the change in the concentration of  active species (parent drug
;and/or active metabolites) at the site of  pharmacological action and the
;therapeutic index of the drug.
;[2372..2376]:substance:"drug"
;[2477..2481]:substance:"drug"
;[2496..2507]:substance:"metabolites"
;[2581..2585]:substance:"drug"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2331..2334] The) (JJ:[2335..2343] clinical)
          (NN:[2344..2356] significance))
      (PP (IN:[2357..2359] of)
        (NP (DT:[2360..2361] a) (JJ:[2362..2371] metabolic)
            (NN:[2372..2376] drug) (NN:[2378..2389] interaction))))
    (VP (VBZ:[2390..2397] depends)
      (PP-CLR (IN:[2398..2400] on)
        (NP
          (NP
            (NP (DT:[2401..2404] the) (NN:[2405..2414] magnitude))
            (PP (IN:[2415..2417] of)
              (NP
                (NP (DT:[2418..2421] the) (NN:[2422..2428] change))
                (PP (IN:[2429..2431] in)
                  (NP
                    (NP (DT:[2432..2435] the) (NN:[2436..2449] concentration))
                    (PP (IN:[2450..2452] of)
                      (NP
                        (NP (JJ:[2454..2460] active) (NN:[2461..2468] species))
                        (PRN (-LRB-:[2469..2470] -LRB-)
                          (NP
                            (NP (NN:[2470..2476] parent) (NN:[2477..2481] drug))
                            (CC:[2482..2488] and/or)
                            (NP (JJ:[2489..2495] active)
                                (NNS:[2496..2507] metabolites)))
                          (-RRB-:[2507..2508] -RRB-))))
                    (PP-LOC (IN:[2509..2511] at)
                      (NP
                        (NP (DT:[2512..2515] the) (NN:[2516..2520] site))
                        (NP (IN:[2521..2523] of)
                            (JJ:[2525..2540] pharmacological)
                            (NN:[2541..2547] action)))))))))
          (CC:[2548..2551] and)
          (NP
            (NP (DT:[2552..2555] the) (JJ:[2556..2567] therapeutic)
                (NN:[2568..2573] index))
            (PP (IN:[2574..2576] of)
              (NP (DT:[2577..2580] the) (NN:[2581..2585] drug)))))))
    (.:[2585..2586] .)))

;sentence 18 Span:2587..2750
;The smaller the  difference between toxic and effective concentration, the
;greater the likelihood  that a drug interaction will have serious clinical
;consequences.
;[2693..2697]:substance:"drug"
(SENT
  (FRAG
    (NP
      (NP (DT:[2587..2590] The) (JJR:[2591..2598] smaller))
      (NP
        (NP (DT:[2599..2602] the) (NN:[2604..2614] difference))
        (PP (IN:[2615..2622] between)
          (NP
            (NP (JJ:[2623..2628] toxic)
              (NML-1 (-NONE-:[2628..2628] *P*)))
            (CC:[2629..2632] and)
            (NP (JJ:[2633..2642] effective)
              (NML-1 (NN:[2643..2656] concentration)))))))
    (,:[2656..2657] ,)
    (NP
      (NP (DT:[2658..2661] the) (JJR:[2662..2669] greater))
      (NP
        (NP (DT:[2670..2673] the) (NN:[2674..2684] likelihood))
        (SBAR (IN:[2686..2690] that)
          (S
            (NP-SBJ (DT:[2691..2692] a) (NN:[2693..2697] drug)
                    (NN:[2698..2709] interaction))
            (VP (MD:[2710..2714] will)
              (VP (VB:[2715..2719] have)
                (NP (JJ:[2720..2727] serious) (JJ:[2728..2736] clinical)
                    (NNS:[2737..2749] consequences))))))))
    (.:[2749..2750] .)))

;sentence 19 Span:2751..2889
;Thus, careful  evaluation of potential drug interactions of a new drug
;candidate during the  early stage of drug development is essential.
;[2790..2794]:substance:"drug"
;[2817..2821]:substance:"drug"
;[2859..2863]:substance:"drug"
(SENT
  (S
    (ADVP (RB:[2751..2755] Thus))
    (,:[2755..2756] ,)
    (NP-SBJ
      (NP (JJ:[2757..2764] careful) (NN:[2766..2776] evaluation))
      (PP (IN:[2777..2779] of)
        (NP
          (NP (JJ:[2780..2789] potential) (NN:[2790..2794] drug)
              (NNS:[2795..2807] interactions))
          (PP (IN:[2808..2810] of)
            (NP (DT:[2811..2812] a) (JJ:[2813..2816] new) (NN:[2817..2821] drug)
                (NN:[2822..2831] candidate)))))
      (PP-TMP (IN:[2832..2838] during)
        (NP
          (NP (DT:[2839..2842] the) (JJ:[2844..2849] early)
              (NN:[2850..2855] stage))
          (PP (IN:[2856..2858] of)
            (NP (NN:[2859..2863] drug) (NN:[2864..2875] development))))))
    (VP (VBZ:[2876..2878] is)
      (ADJP-PRD (JJ:[2879..2888] essential)))
    (.:[2888..2889] .)))

;section 20 Span:2893..2911
;Publication Types:
(SEC
  (NP (NNP:[2893..2904] Publication) (NNP:[2905..2910] Types) (::[2910..2911] :)))

;section 21 Span:2917..2923
;Review
(SEC
  (NP (NNP:[2917..2923] Review)))

;section 22 Span:2929..2945
;Review, Academic
(SEC
  (NP (NNP:[2929..2935] Review) (,:[2935..2936] ,) (NNP:[2937..2945] Academic)))

;section 23 Span:2949..2993
;PMID: 9839089 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2949..2953] PMID) (::[2953..2954] :) (CD:[2955..2962] 9839089)
        (NN:[2963..2964] -LSB-) (NNP:[2964..2970] PubMed) (::[2971..2972] -)
        (NN:[2973..2980] indexed) (IN:[2981..2984] for)
        (NNP:[2985..2992] MEDLINE) (-RRB-:[2992..2993] -RSB-)))
